You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK (360Dx) – Researchers at Cleveland HeartLab have developed a pair of proteomic tests for measuring cholesterol efflux capacity (CEC) and assessing patient risk of coronary artery disease (CAD).
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.